Abstract 61P
Background
CCN growth factor family regulates a variety of biological events such as cell proliferation, cell invasion, cell differentiation, apoptosis, and growth inhibition. Cysteine-rich protein 61 (Cyr61) is one of six secreted proteins in the CCNs. It has been shown that Cyr61 plays an important role in tumorigenesis and carcinogenesis in glioma, breast cancer, and gastric cancer, and others. However, Cyr61 has not yet been elucidated on the tumorigenesis, proliferation, and invasion of hepatocellular carcinoma, and needs to be researched and discovered. In this study, the HGF-mediated association of Cyr61, interleukin-8 (IL-8), and NF-κB (Nuclear factor kappa-light-chain-enhancer of activated B cells) and cancer cell proliferation and invasion were investigated in two types of hepatoma cell lines.
Methods
In this study, cell culture, cDNA microarray analysis, western blotting, Real-time Polymerase chain reaction, Zymography, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, Cyr61 knock-down with short hairpin RNA (shRNA), chromatin immunoprecipitation assay, Standard two chamber invasion assay.
Results
First, we confirmed that the expression level of Cyr61 was up-regulated by HGF (hepatocyte growth factor) in hepatoma cells. To identify associated pathway of HGF-induced Cyr61 about IL-8, NF-κB expression, the cells were treated with PI3K (Phosphoinositide 3-kinase) inhibitor (LY294002) and then analyzed by Western blotting. The HGF-mediated IL-8 and NF-κB levels were decreased with LY294002. The role for Cyr61 associated with IL-8 and NF-κB was determined by knock down cell of Cyr61. Cyr61-sh RNA cells showed a decreased level of IL-8 and NF-κB. HGF-mediated cell proliferation and invasion were decreased in Cyr61 knock down cell.
Conclusions
These results suggest that Cry61 plays an important role in cell proliferation and metastasis in hepatocellular carcinoma, and Cry61 may be a novel target for the prevention of progression and treatment of hepatocellular carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
13P - Universal prospects of cryopreserved umbilical cord blood CD34+ progenitor cell-derived NK cells: Clinical and preclinical evaluation of non-engineered and genetically engineered candidates
Presenter: Anna-Maria Georgoudaki
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - Lentivirally overexpressed c-Myc promoter binding protein (MBP-1) localizes in the cytoplasm of human cutaneous melanoma cell lines increasing cell proliferation and glycolysis rate
Presenter: Miriam Hippner-Kunicka
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - Enhancement Platform for immune Cells (EPiC): invIOs’s innovative cell-therapy platform for creating personalized cancer treatments
Presenter: Mario Kuttke
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Melatonin modulates energy metabolism and kinases signaling in ovarian cancer cells
Presenter: Luiz Gustavo Chuffa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - New therapeutic target in triple-negative breast cancer for enhancing PARP inhibitor efficacy and stimulating the anti-tumour immune response
Presenter: Marina Rodriguez-Candela Mateos
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - PARP1 trapping and hyperactivation by the decoy agonist OX425 induces DNA repair abrogation and a robust anti-tumor immune response
Presenter: Vlada Zakharova
Session: Cocktail & Poster Display session
Resources:
Abstract
20P - Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
Presenter: Pranshu Sahgal
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Cross-resistance between platinum-based chemotherapy (PlCh) and PARP inhibitors (PARPi) in castration-resistant prostate cancer (CRPC)
Presenter: Peter Slootbeek
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage
Presenter: Wafaa Ramadan
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Synthetic lethality by targeting RHEB in ARID1A-mutated luminal breast cancer
Presenter: Deniz Gulfem Ozturk
Session: Cocktail & Poster Display session
Resources:
Abstract